(Q34733099)

4 August 2017

1 reference

title

Inhibition of CYP 17, a new strategy for the treatment of prostate cancer (English)

1 reference

4 August 2017

Samer Haidar

3

0 references

author name string

Rolf W Hartmann

1

1 reference

4 August 2017

Peter B Ehmer

2

1 reference

4 August 2017

Markus Hector

4

1 reference

4 August 2017

Joachim Jose

5

1 reference

4 August 2017

Christian D P Klein

6

1 reference

4 August 2017

Stefanie B Seidel

7

1 reference

4 August 2017

Tom F Sergejew

8

1 reference

4 August 2017

Bertil G Wachall

9

1 reference

4 August 2017

Gerald A Wächter

10

1 reference

4 August 2017

Yan Zhuang

11

1 reference

4 August 2017

1 April 2002

1 reference

Archiv der Pharmazie - Chemistry in Life Sciences

4 August 2017

1 reference

4 August 2017

335

1 reference

4 August 2017

4

1 reference

4 August 2017

119-128

1 reference

Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Synthesis and aromatase inhibition of 3-cycloalkyl-substituted 3-(4-aminophenyl)piperidine-2,6-diones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Synthesis and evaluation of steroidal hydroxamic acids as inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

4-pregnene-3-one-20β-carboxaldehyde: A potent inhibitor of 17α-hydroxylase/C17,20-lyase and of 5α-reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

P450-dependent enzymes as targets for prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, a selective mechanism-based inhibitor of cytochrome P450(17 alpha) (steroid 17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1521-4184%28200204%29335%3A4%3C119%3A%3AAID-ARDP119%3E3.0.CO%3B2-%23

10.1002/1521-4184(200204)335:4<119::AID-ARDP119>3.0.CO;2-#

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference